Dr. Michael Andrew Rogawski, MD

Dr. Rogawski practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Rogawski's NPI, 1538357033, was assigned on October 9, 2007. Dr. Rogawski graduated from Yale School of Medicine in 1980. Dr. Rogawski holds California license G88105.

Dr. Rogawski's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Rogawski's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Rogawski to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rogawski practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Rogawski's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dmand AI has Dr. Rogawski's licenses on file in 2 states: California and Maryland.

Dmand AI lists fibromyalgia and chronic pain, lower back pain, migraine and chronic headache and thoracic spine disorders among the conditions Dr. Rogawski treats.

CMS data shows 59 Medicare services from Dr. Rogawski across 3 procedure codes in 2024, for 37 Medicare patients. Medicare paid $2,717 for them. Every service was in an office.

CMS counts 37 Medicare patients who saw Dr. Rogawski in 2024. The largest group is 65 to 74, with 12 patients. 75% of them have arthritis, and 62% have high blood pressure. 32% are also on Medicaid. Their average risk score is 1.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rogawski's median patient age at 48, with 78% women.

In 2024, Dr. Rogawski wrote 481 Medicare Part D claims for 40 patients. 60% of them were for generic drugs. CMS names the drug for 380 of them, across 12 drugs with 11 or more claims each, at $218,469 in total drug cost. In 2023, CMS named 308 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Rogawski for performance year 2024, reported as part of a group. Dr. Rogawski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rogawski as offering telehealth.

Dmand AI links 161 papers to Dr. Rogawski, published from 2004 to 2025. 2017 was the busiest year, with 6. The most frequent topics are Anticonvulsants, Seizures and Disease Models, Animal. Dr. Rogawski has published most often in Epilepsia. Dr. Rogawski's most frequent co-authors are Adam Lindsay Hartman, MD, Randi Jenssen Hagerman, MD and Carl E. Stafstrom, MD, PhD.

Dmand AI links Dr. Rogawski to 2 clinical trials. Conditions studied include Epilepsy, Epilepsy, Post-Traumatic and Brain Diseases.

CMS Open Payments shows 80 general payments to Dr. Rogawski from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 72% of the total. Marinus Pharmaceuticals, Inc. paid the most, $70,890. It also lists 3 research payments totaling $26,764 in 2019.

Dmand AI lists 1 award for Dr. Rogawski, most recently CMS Stage 1 EHR in 2012.

Dr. Rogawski graduated from Yale School of Medicine in 1980. Dr. Rogawski is a member of AES.

Dr. Rogawski is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.